Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV)

Core Viewpoint - Roivant Sciences Ltd. (NASDAQ:ROIV) is recognized as one of the best growth stocks under $25, with mixed opinions from Wall Street following positive results from its Phase 3 VALOR study for Brepocitinib in dermatomyositis [1] Group 1: Analyst Ratings - Brian Cheng from J.P. Morgan has reiterated a Buy rating on Roivant Sciences with a price target of $20 [2] - Chi Meng Fong from Bank of America Securities has maintained a Hold rating with a price target of $16.5 [2] Group 2: Study Progress and Market Concerns - The Phase 3 VALOR study has shown promising progress, but Fong anticipates limited immediate growth potential due to the launch targeting only a limited referral center [3] - Fong also expressed concerns regarding the competitive market for IMVT-1402, which is being developed for Graves' disease and other autoimmune diseases [4] - The ongoing LNP litigation against major players like Pfizer and Moderna could adversely affect Roivant Sciences' financial health [4] Group 3: Company Overview - Roivant Sciences is a biotechnology company focused on accelerating the development and commercialization of important medicines [5]